Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

ADA 2026
This is the logo of the provider
ADA 2026 5 - 8 June 2026

Exploring semaglutide's effect on the ASCVD-related proteomic signature and their prediction of MACE in SELECT

Authors :

Maria Dermit1;  Alejandro Aguayo-Orozco2; Anne-Mette Bjerregaard3; Fausto Capelluto4; Helen M. Colhoun5; Bjarke Follin3; Kristian Hessellund3; A. Michael Lincoff6; Ildiko Lingvay7; Jorge Plutzky8; Jonas Andreas Sibbesen3; Signe Stensen3; Peter E. Weeke3; Tobias N. Wistisen3; Lotte Bjerre Knudsen4; Steven E. Kahn8
Affiliations
View Details Hide Details
Download .PDF
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Keywords
Obesity
Cardiovascular Disease
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)